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Abstract
Accurate identification of viable myocardium is crucial in patient 
qualification for medical or surgical treatment. Only persons 
with confirmed cardiac viability will benefit from revasculariza-
tion procedures. It is also well known, that the amount of viable 
myocardium assessed preoperatively is the best indicator of 
long term cardiac event free survival after cardiac intervention. 
There are several diagnostic approaches used in current clini-
cal practice for assessment of myocardial viability. Analysis of 
wall thickness or myocardial contraction, evaluation of cardiac 
perfusion or metabolism can be assessed using following 
modalities: Echocardiography, Cardiac Molecular Imaging 
techniques (PET, SPECT), Cardiovascular MR or Cardiovas-
cular CT. The article describes the methods and problems of 
viability assessment in 18FDG PET study. PET imaging has 
proved its accuracy and reproducibility for myocardial ischemia 
and viability assessment. However this unique in its ability for 
showing the particular substrate metabolism technique has 
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unfortunately some disadvantages: currently achieved PET 
resolution is 0.4 cm. However the combined devices multislice 
computed tomography scanners with PET (PET/CT) are now 
widely used in clinical practice. This combination allows for 
wider morphologic assessments: coronary calcium scoring and 
non-invasive coronary angiography may be added to myocardial 
perfusion/metabolic imaging if necessary. 
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Background
Accurate identification of viable myocardium is crucial in 
patient qualification for medical or surgical treatment. Only per-
sons with confirmed cardiac viability will benefit from revasculari-
zation procedures. On the other hand, in patients with preserved 
myocardial viability treated medically the annual cardiac death 
rate increases significantly-up to 16% versus 3.2% in the group 
after revascularization. A meta-analysis [1] showed 80% reduction 
in mortality if such patients had an interventional, revasculariza-
tion treatment. It is also well known, that the amount of viable 
myocardium assessed preoperatively is the best indicator of long 
term cardiac event free survival after cardiac intervention [2]. Pa-
tients with no signs of viable myocardium should not be subjected 
to the risks of invasive surgery, because they don’t have areas of 
myocardium that will show improved function after revasculariza-
tion. According to the results of Allman’s meta-analysis there 
is no significant difference noted between medical therapy and 
revascularization if patients had primarily nonviable myocardium 
(7.7% vs 6.2%) [1]. There are also data demonstrating that after 
revascularization, even in presence of myocardial viability, the 
clinically significant improvement in global left ventricular function 
is noted only in patients with relatively large areas of hibernated 
tissue — > 17% of the left ventricular mass [3]. 
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Diagnostic imaging techniques  
for viability assessment
There are several diagnostic approaches used in current clini-
cal practice for assessment of myocardial viability. Analysis of wall 
thickness or myocardial contraction, evaluation of cardiac perfu-
sion or metabolism can be assessed using following modalities: 
Echocardiography, Cardiac Molecular Imaging techniques (PET, 
SPECT), Cardiovascular MR or Cardiovascular CT.
Stress echocardiography
Among all cardiac visualization methods, stress echocardio-
graphy is probably still most commonly used in clinical practice for 
myocardial viability assessment. A rest cardiac wall thickness and 
contractile function can easily be assessed by 2D echocardiog-
raphy. Infusion of either low dose-dobutamine or dipirydamole 
— a pharmacological “stress” agent — allows for the differen-
tiation between irreversibly damaged scar tissue and viable, 
severely hypoperfused, dysfunctional myocardium. Furthermore, 
the myocardial contrast echocardiography with venous injection of 
contrast can also define the presence of coronary artery disease 
and enhance the determination of myocardial viability. The global 
assessment of the heart using the new ECHO technologies such 
as instantaneous full volume echo imaging will further improve 
diagnostic accuracy of echocardiography. Advantages of echo-
cardiography include its relatively low cost and short time of the 
examination. The study is also easy to perform with widely avail-
able equipment. The disadventages include high interobserver 
variability and subjectivity of the interpretation. Poor visualization 
is the most common limitation of this technique. Diagnostic ac-
curacy of the test appears unfortunately especially decreased in 
patients with severely impaired cardiac and lung function- the 
group who might mostly benefit from myocardial viability as-
sessment. A meta-analysis referred to ECHO pharmacological 
stress test has shown that the sensitivity (84%) and specificity 
(81%) is decreasing while the cardiac left ventricular dysfunction 
increases [2].
Cardiac magnetic resonance
Cardiac magnetic resonance is a well validated method for 
assessment of myocardial masses and size, for quantification of 
ventricular function. New, fast scanning MR methods allow for 
the analysis of myocardial perfusion and cardiac dysfunction (at 
rest and during the pharmacological stress study), for detection 
of myocardial viability and visualization of irreversibly changed 
myocardium-scar tissue. Direct visualization of the scar is possible 
by a technique called “delayed enhancement “(DE CMR). The 
injected contrast medium shows the prolonged accumulation in 
cardiac scar tissue. The DE CMR images are obtained approxi-
mately 10 min after intravenous contrast administration. Cardiac 
MRI offers highest spatial resolution and has recently become 
the new gold standard for quantification of myocardial scar and 
for evaluation of myocardial viability. Its superior spatial resolution 
allows for visualization of small, subendocardial lesions. Because 
18FDG-PET was until recently the gold standard for myocardial 
viability assessment, in many papers MRI techniques are judged 
comparatively. In most papers approximately 95% concordance 
between techniques is noted [4]. MR technique appeared to be 
more accurate than molecular imaging especially for non-transmu-
ral scar recognition. However, despite the numerous adventages, 
there are also some disadventyages: the study is contraindicated in 
patients with metallic implants and in persons with claustrophoby. 
The study is relatively long, the good patient’s cooperation is ne-
cessary (for example the breath holding). 
Cardiac CT
Cardiac CT is currently used in clinical practice for evaluation 
of cardiac anatomy — mainly coronary arteries and coronary 
lumen atherosclerotic narrowing, for quantitative assessment of 
artery calcifications (Calcium Score) — which are pivotal to the 
prognosis of patients with coronary artery disease. The whole po-
tential of cardiac CT has not been fully realized. Current available 
dual source CT scanners allow for the morphological assessment 
of coronary arteries and myocardial perfusion during one scan. 
Multidetector ECG-gated CT (MDCT) has recently become more 
available for routine use. MDCT allows not only for assessment of 
coronary artery morphology, but also ventricular morphology and 
function. Cardiac cells viability can be evaluated on the basis of CT 
residual myocardial blood flow assessment. Some studies have 
shown similar to DE CMR late enhancement phenomenon present 
in CT studies. The delayed images allow for differentiating acutely 
infarcted from viable myocardium. After the intravenous iodine 
contrast medium injection, the early MDCT images show the “cold 
spot” in the area supplied by the occluded coronary artery. On the 
second scan acquired later (about 10 min) without another con-
trast medium injection, the relatively high contrast accumulation in 
comparison to surrounding healthy muscle remains in the area of 
hypoperfused myocardium, due to contrast washout impairment. 
The comparison studies demonstrated similar accuracy of CT and 
CMR [5]. The limitation of cardiac CT include low temporary resolu-
tion — which is improving but yet still limiting functional studies. 
Cardiac molecular imaging techniques
Both SPECT and PET techniques allow for the identification of 
ischemic but viable myocardium, analyzing myocardial perfusion 
and function (in gated exams). PET may also be used to evalu-
ate myocardial metabolism. The thallium redistribution SPECT 
studies present 201Tl uptake depending on cell membrane 
integrity and thus myocyte viability. Additionally, the initial uptake 
of radiopharmaceutical shows the regional perfusion, allowing 
for thallium stress perfusion study, and assessment of coronary 
perfusion reserve. The sensitivity of the test is high (88%), although 
the meta-analysis has shown that the test may overestimate the 
viability (specificity of 49%) [2].
Over the last years FDG PET was the gold standard for myocar-
dial metabolism assessment. This technique requires comparison 
of myocardial perfusion (using a perfusion PET or SPECT) with 
functional metabolic images obtained with FDG. The myocardial 
perfusion and metabolic uptake pattern is analyzed and compared. 
The mismatch between perfusion and function — lack of perfu-
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sion, while preserved glucose uptake- indicates the presence of 
severely impaired but viable myocardium (Figure 1). Myocardial 
segment which indicates normal or even decreased, but still 
present perfusion are naturally classified as viable (normal or 
hypoperfused myocardium). Those segments also maintain me-
tabolism, but not necessarily show 18FDG uptake: the myocardial 
substrate demand is dependent on the metabolic and nutritional 
status (Figure 2A and B).
Physiologic cardiac metabolism
Normal cardiac muscle is able to produce energy from dif-
ferent substrates: free fatty acids (FFA), glucose and pyruvate. 
The proportion depends on the substrate delivery, hormone 
levels (mainly insulin) cardiac work load and perfusion. Different 
substrate utilization is observed in normal heart in fasting and 
postprandial stage. FFA are preferred substrate and account for 
up to 70% of cardiac energy metabolism - in fasting condition, 
in terms of normal oxygen supply (Figure 3B). The carbohydrate 
(glucose and pyruvate) metabolism reaches only 30% of cardiac 
muscle demand. The uptake of carbohydrates in fasting stage 
is generally low, but can be variable and heterogeneous (Figure 
3A). On the contrary: in postprandial state glucose is a preferred 
energy source, while fatty acid oxidation is suppressed (Figure 4). 
Understanding those physiological changes in cardiac metabolism 
is crucial for proper metabolic 18F-FDG PET study interpretation. 
The lack of FDG uptake is suggesting not only the presence of 
non viable (scar tissue) but also utilization of substrates other than 
glucose. Therefore the perfusion and FDG metabolic study must 
be interpreted together. 
Figure 1. Viable myocardium uptake pattern. Comparison of 
99mTc-MIBI perfusion (left column) and 18FDG uptake (right column) 
There is perfusion/metabolic mismatch, typical for myocardial hiberna-
tion. The extensive apical, periapical and posterior wall perfusion de-
fect show high 18FDG uptake reflecting presence of glucose utilization 
and preserved myocardial metabolism
Figure 2. Viable myocardium uptake patterns: comparison of 
99mTc-MIBI perfusion (upper rows) and 18FDG uptake (lower rows). 
A. There is a perfusion/metabolic match, typical for normal, viable my-
ocardium. The picture show normal, homogenous perfusion and glu-
cose metabolism. This perfusion/metabolic uptake pattern is typical for 
18FDG glucose load protocol; B. This perfusion/metabolic mismatch 
— called “reversed mismatch” (posterior wall — yellow arrows ) is 
consistent with presence of myocardial viability. The picture shows the 
presence of 99mTc-MIBI perfusion (upper row) with reduced 18FDG 
uptake (lower row). There is no 18FDG uptake in posterior wall, due to 
preferential FFA metabolism. Additionally there is also perfusion/meta-
bolic mismatch in anterior wall, typical for myocardial hibernation (red 
arrows). This perfusion/metabolic uptake pattern is typical for 18FDG 
administration in fasting condition
 A
 B
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Figure 4. 18FDG PET/CT fusion images. Changes in FDG uptake in normal myocardium according to the nutritional status: postprandial condi-
tions: 18FDG uptake is high due to facilitated glucose transport and utilization by normal myocytes, caused by release of endogenous insulin as 
an answer to increased plasma glucose
 A  B
Figure 3. 18FDG PET/CT fusion images. Changes in FDG uptake in 
normal myocardium according to the nutritional status-fasting condi-
tions. A. The heterogeneous non specific myocardial 18FDG uptake is 
not reflecting the myocardial pathologic condition. The interpretation 
is dependent on the myocardial perfusion; B. 18FDG uptake is low, 
due to relatively low glucose and insulin levels and high free fatty acids 
level
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Cardiac metabolism in pathologic conditions
There are several pathologic conditions altering the normal 
preferential FFA cardiac uptake normally observed in fasting 
condition. Ageing, cardiomyopathy (dilated and hypertrophic), 
ischemia, hibernation - are known reasons for preferential glucose 
utilization. On the contrary FFA are still preferentially used even in 
postprandial stage if patient is diabetic, insulin resistant or if high 
blood lipid levels are present. 
Ischemia, hibernation
In the first line cardiac metabolic response to the acute 
disturbance such as ischemia is to switch myocardial substrate 
use from FFA to oxidation of glucose, lactate and glycogen, 
to maintain sufficient fuel supply during increased workload. 
Therefore on PET scan acquired in the fasting condition, glucose 
is preferentially accumulated in ischemic myocardium, and ap-
pears as a “hot spot” due to preferential FFA utilization by the 
rest of normal, non-ischemic myocardium (Figure 2B). Myocar-
dial uptake of 18F-FDG is reflecting not only aerobic but also 
anaerobic glycolytic flux [6]. In normally functioning myocardium 
all available substrates for energy production are metabolized via 
oxygen dependent pathways. Only the hypoperfused myocardium 
is forced to produce energy via non oxidative metabolism. There-
fore two cardiac FDG PET study protocols should be considered: 
Analysis of cardiac FDG uptake in fasting stage (fasting protocol) 
should be performed if acute ischemia is suspected. This protocol 
is preferred also for detection of metabolic changes due to prior 
ischemia in myocardium with apparent normal contractile function 
(metabolic memory phenomenon, after stress inducted ischemia). 
Assessment of cardiac viability while myocardial hibernation is sus-
pected, demands to force the myocardium for primarily glucose 
utilization and registration of cardiac images in postprandial stage. 
Thus, to identify viable myocardium in mechanical dysfunctioning 
areas glucose loading protocols are preferred, because viable 
cells will accumulate preferentially 18F-FDG, whereas necrotic 
(scar) tissue will not show the deoxyglucose uptake (Figure 5).
The following example present typical for hibernation 
metabolic and perfusion uptake pattern — 99mTc-MIBI 
SPECT/ 18FDG PET mismatch.
Case
66-years-old male who has a history of coronary artery di-
sease, status post myocardial infarction involving the inferior and 
infero-lateral wall (Figure 6). 
SPECT Findings
The dipiridamole-stress 99mTc-MIBI examination revealed 
severe perfusion defect in apical, distal segments of anterior wall, 
in inferior, infero-lateral and infero-septal wall. The defects in apical 
and anterior wall region show partial reversibility. Some border 
reversibility at rest is seen around the fixed defect in inferior and 
infero-lateral wall. The extent of the stress defect is calculated as 58 
percent of the left ventricle, the rest perfusion defect is covering 
43% of the left ventricle. 
SPECT Conclusions
The rest and stress SPECT study revealed the transmural 
scar involving the apical, inferior, infero-lateral and infero-septal 
wall with borderline ischemia. Evaluation of myocardial viability 
is requested (Figure 7). 
18FDG-PET findings
There is slight inhomogenous, glucose metabolism seen in 
the whole left ventricular muscle. 
Impression
There is viable, hibernated muscle present in the area matching 
the resting SPECT perfusion defect. The normal perfused myocar-
dium shows glucose uptake similar to the hibernated area. The 
result of the PET/SPECT study reflex the muscle with preserved 
viability but compromised (Figure 8).
Discussion
Assessment of cardiac viability while myocardial hibernation 
is suspected, demands to force the myocardium for primarily glu-
cose utilization and registration of cardiac images in postprandial 
stage. To identify viable myocardium in mechanical dysfunctioning 
areas glucose loading protocols are preferred, because viable 
Figure 5. Comparison of 99mTc-MIBI perfusion (left column) and 
18FDG uptake (right column) There is perfusion/metabolic match, typi-
cal for scar tissue (yellow arrows). The picture shows severe, extensive 
perfusion and glucose metabolism defect. This perfusion/metabolic 
uptake pattern is typical for 18FDG glucose load protocol, where the 
facilitated glucose transport causes the “glucose switch” and preferen-
tial glucose uptake by whole viable cardiac muscle
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Figure 6. 99mTc-MIBI perfusion SPECT study. A. Upper rows: dipirydamole stress study; B. lower rows: rest study
Figure 7. Glucose metabolism PET study with 18FDG
cells will accumulate preferentially 18F-FDG, whereas necrotic 
(scar) tissue will not show the deoxyglucose uptake. This case 
shows the FDG PET uptake pattern typical for adequate “glucose 
switch” after glucose load protocol. The study confirmed preserved 
viability in functional impaired myocardium. 
Dilated cardiomyopathy and left ventricular 
hypertrophy
The cardiac hypertrophy or dilated cardiomyopathy are 
chronic diseases in which the cardiac metabolic changes occur 
at a transcriptional level. The genetic profile of the injured heart 
is switching for adaptation to a “fetal- like” profile that favors glu-
cose over the FFA [7] (Figure 9). The current works are carried on 
the investigation of the connection between the cardiac hypertro-
phy and FFA oxidation impairment. It was confirmed that the activ-
ity of the process of myocardial FFA oxidation is an independent 
predictor of left ventricular mass in hypertrophy [8]. Not only the 
FDG-PET study, but also other radiopharmaceuticals allow for 
FFA oxidation measurements. The PET study with the palmitate 
— a long-chain fatty acid labeled with 11C is directly reflecting 
the activity of the FFA beta- oxidation. Studies on glucose and 
palmitate kinetics have shown that FFA uptake and metabolism 
is lower in cardiomyopatic patients than in controls [9]. The 
severity of this metabolic disturbance correlates good with the 
patient’s clinical condition. 
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Diabetes, obesity and insulin resistance
In diabetic patients cardiac metabolism rely mainly on FFA 
as a substrate for energy production. Utilization of FFA meets 90–
–99% of cardiac oxygen usage (MVO2). Normally in fasting stage 
and non-diabetic patients, FFA utilization is responsible for 70% 
MVO2, and glucose for the rest 30% [10]. The normal cardiac 
ability to choose the substrates for energy production in cases of 
diabetes mellitus is impaired. In consequence, the diabetic heart 
in terms of increased myocardial work (e.g. stress) is unable in-
crease glucose uptake and metabolism to maintain the adequate 
MVO2 , this causes the higher sensitivity to ischemia (Figure 10, 
11). Additionally the increased myocardial lipid accumulation may 
lead to cardiac cells injury — in consequence the apoptosis and 
electrical instability [11]. Increased body mass index (BMI) also 
Figure 8. Evaluation of myocardial perfusion and metabolic activity: stress-rest single-photon emission computed tomographic (SPECT) myocar-
dial perfusion imaging with 99mTc-MIBI and 18FDG PET metabolic imaging. The dipirydamole-stress 99mTc-MIBI perfusion study (A) shows the 
extensive, apical, antero-septal, distal anterior, inferior, infero-lateral, and infero-septal wall perfusion defect (58% of the left ventricle). At rest (B), the 
perfusion defect shows partial reversibility, which reflect the transmural scar with the borderline significant stress inducted ischemia. A. 99mTc-MIBI 
stress perfusion slices; B. 99mTc-MIBI rest perfusion slices; C. 18FDG-PET scan: cardiac glucose metabolism; D. Exercise 99mTc-MIBI perfusion 
polar map (“bulls eye” display); E. Rest 99mTc-MIBI perfusion polar map (“bulls eye” display); F. 18FDG polar map (“bulls eye” display)
Figure 9. 18FDG PET/CT fusion images. Changes in FDG uptake in cardiomyopathy. The 18FDG uptake in hypertrophic myocardium is high, due 
to preferential uptake despite the fasting status and high FFA blood level
influences the cardiac metabolism. It was shown, that FFA me-
tabolism increases in obese patients. PET acetate and palmitate 
studies on young obese women confirmed the presence of cardiac 
metabolic shift toward FFA, which was positively correlated with 
worsening insulin resistance [12]. 
Glucose load protocols
There is no standard protocol for forced cardiac glucose 
uptake. The main goal is to shift cardiac metabolism to glucose 
utilization, by increasing the blood glucose level which is stimula-
ting the endogenous insulin response and increase the intracellular 
glucose transport. The intravenous or oral glucose load may be 
used, the other possible choice is oral acipimox administration. The 
main goal of patient preparation, independent from the protocol 
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– is to push the myocardium for preferential glucose utilization. All 
the protocols require keeping the patient fasting for at least 6 hr, 
This is necessary to induce proper endogenous insulin response. 
Shorter fasting time could depress this physiological process. 
A sample protocols are given below:
Oral glucose
This protocol is preferred in most nuclear medicine units because 
of its simplicity. The patient must be nondiabetic, with good blood 
glucose control, after at least 6 hours of fasting. For optimal FDG 
cardiac uptake the blood glucose has to be held at 100 to 140 mg/ml 
at FDG injection time. The protocol starts with oral glucose load of 25 
to 100 g. The blood glucose has to be measured periodically during 
the next 60 min. The blood glucose level must fall sufficiently at 60 min 
after oral glucose administration. If the blood glucose ranges between 
100–140 mg/dL, the FDG can be injected. The protocol is easy to im-
plement and easy to perform in routine practice, but often needs some 
modification dependent on the blood glucose level. If the blood glu-
cose rises over 140 mg/dl (140–160 mg/dL) the 2 U of regular insulin 
has to be additionally injected. The injected insulin amount should 
be further increased if the blood glucose reaches higher level. The 
amount of 1–2 U insulin should be injected on every 10 mg/dL over 
the maximal allowed (140 mg/dL) blood glucose level [13]. 
Intravenous glucose 
The intravenous glucose administration is more complicated 
but it avoids the problems with variable gastrointestinal glucose 
absorption time. This protocol can be used if the patient is non 
diabetic and his/her fasting blood glucose is less than 110 mg/mL. 
The most convenient way is to use the hyperinsulinemic euglyce-
Figure 10. 18FDG PET and 99mTc-MIBI study: the 18FDG is present in the blood pool, there is no myocardial tracer uptake due to insulin resis-
tance (upper row). The extensive perfusion defect shown on perfusion scan (lower row, yellow arrows) in this case can reflect both-scar tissue or 
hibernating myocardium. The result of the metabolic PET study make the perfusion study inconclusive
Figure 11. 18FDG PET/CT fusion images. No myocardial 18FDG uptake due to insulin resistance
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mic clamp which is minimizing changes in the FFA, insulin and 
glucose levels, allowing for optimal myocardial 18F-FDG imaging. 
Still, despite the optimization, there is up to 10–15% of uninterpre-
table cases noted [6].
Hyperinsulinemic-euglycemic clamp
This protocol is effective both in diabetes and patients with 
normal glucose tolerance. It is used mostly in investigational 
studies, for exclusion of differences in glucose intestinal absorp-
tion. The protocol starts with the blood glucose level estimation, 
repetitive measurements should be carried on every 15 min until 
18FDG injection. The insulin should be injected in declining infusion 
rates-starting with 0.16 U/min/kg for 4 minutes, than 0.08 U/min/kg 
for next 3 minutes and 0.04 U/min/kg at 8th minute. Co-infusion 
of 20% dextrose should be carried on in order to achieve the 
constant, euglycemic blood glucose concentration. The 18FDG 
is injected when blood glucose reach the range 80–110 mg/dl 
and remains constant for at least approximately 30 min. For the 
best image quality, the insulin and dextrose infusion should be 
maintained for another 30 min [13].
Glucose-insulin infusion
The following protocol is often used both in diabetes and 
non-diabetes patients, it is less time consuming and less com-
plicated than hyperinsulinemic euglycemic clamp. The protocol 
starts with the priming regular insulin injection — 6 (10) U, if the 
initial blood glucose level exceed 100 (140) mg/dl. The following 
co-infusions: insulin (100 U diluted in 500 ml 0.9% saline solution) 
at a rate of 1,2 ml/kg/min and 20% dextrose at a rate 1,8 ml/kg/h 
should be carried on for next 60 min. If the blood glucose level 
is maintained in the range of 80–140 mg/dl, the 18FDG should be 
injected at 30 min [14].
Acipimox oral administration
Oral acipimox administration inhibits the peripherial lipoly-
sis and thus decreases free fatty acids plasma level. The lack 
of this energetic substrate is causing the preferential glucose 
utilization by the myocardium (glucose switch). The usual protocol 
indicate the oral 250 mg acipimox administration 90 to 60 min 
prior to 18F-FDG injection, after the overnight fasting [4]. Some 
protocols include additional carbohydrate-protein-rich meal after 
acipimox administration. 
The more detailed description of the mentioned above proto-
cols are described in guidelines published by the American Society 
of Nuclear Cardiology and the Society of Nuclear Medicine [15].
PET imaging has proved its accuracy and reproducibi lity 
for myocardial ischemia and viability assessment. However 
this unique in its ability for showing the particular substrate me-
tabolism technique has unfortunately some disadvantages: PET 
imaging requires equipment and radiotracers synthesis onsite, 
some of them may not be widely available. The patient prepara-
tion is mandatory for optimization of diagnostic accuracy, the 
protocols are especially technically challenging in patients with 
metabolic disorders such as diabetes or insulin resistance. The 
technique has also comparatively lower spatial resolution in com-
parison to the MRI study. Currently achieved PET resolution is 0.4 
cm, but the combined devices multislice computed tomography 
scanners with PET (PET/CT) are now sufficiently accessible in 
clinical practice. This combination allows for wider morphologic 
assessments: coronary calcium scoring and non-invasive coronary 
angiography may be added to myocardial perfusion/metabolic 
imaging if necessary. 
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